Videos

The director of movement disorders at the Banner Sun Health Research Institute discussed the challenges in diagnosing atypical Parkinsonian disorders and the potential role of biomarkers in improving diagnostic accuracy. [WATCH TIME: 5 minutes]

The pediatric neurologist at Johns Hopkins Medicine discussed the importance of early diagnosis in SMA, and the notable barriers that come with obtaining disease-modifying therapies. [WATCH TIME: 4 minutes]

The director of the Movement Disorders Center at Baylor University Medical Center in Dallas, a part of Baylor Scott & White Health, discussed the current state of treatment for Parkinson disease and gene therapy as a promising treatment for the management of the disease. [WATCH TIME: 5 minutes]

The director of research for internal medicine and geriatrics at Indiana University School of Medicine discussed the advantages digital assessments bring to clinics, and what role they will play in the coming years. [WATCH TIME: 3 minutes]

The associate professor in the department of population and quantitative health sciences at Case Western Reserve University School of Medicine talked about the presentation of multiple sclerosis in Latinx individuals compared with White Americans. [WATCH TIME: 5 minutes]

The PhD student in the department of electrical and computer engineering at Johns Hopkins University discussed the use of artificial intelligence and image harmonization techniques to address the challenges caused by multisite effects in neuroimaging. [WATCH TIME: 4 minutes]

Episode 36 of the AUPN Leadership Minute features Rohit Das, MD, of University of Texas Southwestern Medical Center at Dallas; and David G. Standaert, MD, PhD, of the University of Alabama at Birmingham. [WATCH TIME: 4 minutes]

The assistant professor of neurology at the University of Colorado School of Medicine talked about the importance of addressing family planning with patients with multiple sclerosis. [WATCH TIME: 5 minutes]

The neurologist at NorthShore University Health System in Chicago discussed a retrospective study on patients with multiple sclerosis who switched from high or moderate efficacy disease-modifying therapies to lower efficacy ones. [WATCH TIME: 5 minutes]

The associate professor of neurology at the University of Colorado School of Medicine discussed results of phase 3 studies assessing therapeutics on the impact of fatigue experienced by patients with multiple sclerosis. [WATCH TIME: 5 minutes]

Neurology News Network for the week ending July 29, 2023. [WATCH TIME: 4 minutes]

The associate research professor of neurobiology at Duke University discussed an innovative epigenome editing approach that shows promising prospects for patient improvement, disease prevention, and potential use in Alzheimer disease prophylactic work. [WATCH TIME: 3 minutes]

The chief executive officer at INmune Bio discussed a unique approach from a phase 1 study targeting neuroinflammation in the brain to improve cognitive abilities and maintain memory. [WATCH TIME: 5 minutes]

The chief medical officer at Athira Pharma talked about an exploratory phase 2 trial that showcased the correlation between biomarkers for Alzheimer disease hallmarks and neuroinflammation. [WATCH TIME: 5 minutes]

A duo of experts provide insight on various topics related to the advances in treatment options, diagnosis of the disorder, role of genetics, and potential future research and gene therapies.

Amy Perrin Ross, APN, Patricia Melville, NP-C, Aliza Ben-Zacharia, PhD, DNP, ANP-BC, and John Kramer, PA-C share their advice for facilitating uptake of biosimilars in clinical practices.

Advanced practice providers share how to discuss biosimilars with patients and what resources might be useful for education on biosimilars.

Amy Perrin Ross, APN, Aliza Ben-Zacharia, PhD, DNP, ANP-BC, and John Kramer, PA-C share strategies for implementing biosimilars in clinical practice.

The postdoctoral researcher at The University of Texas Health Science Center at San Antonio talked the gut microbiome and neurological disorders, focusing on the potential role of gut microbiota imbalance in the pathogenesis of conditions like Alzheimer disease. [WATCH TIME: 5 minutes]

Krzysztof Selmaj, MD, PhD, wraps up this series highlighting strategies for educating patients with relapsing-remitting multiple sclerosis (RRMS) about sphinogine-1-phospate (S1P) receptor modulators.

The clinical research associate at the University of Texas Health Science Center at San Antonio discussed a study that explores the relationship between cognitive function and gut microbiome structure in middle-aged adults from the Framingham Heart Study cohort. [WATCH TIME: 4 minutes]

Krzysztof Selmaj, MD, PhD, presents the key results on the safety of other sphinogine-1-phospate (S1P) receptor modulators, such as fingolimod and ponesimod, in the treatment of multiple sclerosis (MS).

Krzysztof Selmaj, MD, PhD, presents the results of a pooled safety study of ozanimod as treatment for relapsing-remitting multiple sclerosis (RRMS).

Krzysztof Selmaj, MD, PhD, provides key clinical considerations when switching patients with multiple sclerosis (MS) to sphinogine-1-phospate (S1P) receptor modulator treatment.

Krzysztof Selmaj, MD, PhD, provides his clinical expertise on strategies to monitor patients with relapsing-remitting multiple sclerosis (RRMS) taking sphinogine-1-phospate (S1P) receptor modulators.

Krzysztof Selmaj, MD, PhD, discusses the side effects of sphinogine-1-phospate (S1P) receptor modulators, highlighting particular adverse events clinicians should be aware of when treating multiple sclerosis (MS).

Krzysztof Selmaj, MD, PhD, explains the tissue selectivity of sphinogine-1-phospate (S1P) receptor modulators and the clinical considerations that arise when treating multiple sclerosis (MS).

Krzysztof Selmaj, MD, PhD, discusses the treatment landscape for relapsing-remitting multiple sclerosis (RRMS) and where sphinogine-1-phospate (S1P) receptor modulators fit in.

The researcher in the department of neurochemistry at the University of Gothenburg in Sweden discussed bloodspot cards as a promising method for collecting blood samples in Alzheimer disease research. [WATCH TIME: 4 minutes]

The genetic epidemiologist at the University of Pennsylvania talked about a collaboration of sites and analysis groups across the US to create a vast collection of genetic data on patients living with Alzheimer disease. [WATCH TIME: 5 minutes]